Toshihiro Kitahashi

A self-setting TTCP-DCPD apatite cement for release of vancomycin

Vancomycin (VCM), a methiciline-cefem resistant Staphylococcus aureus (MRSA)-specific antibiotic, was incorporated in a self-setting tetracalcium phosphate (TTCP)-dicalcium phosphate dihydrate (DCPD) apatite cement that hardened isothermally into a hydroxyapatite (HAP) phase with crystallinity similar to that of host bone. Effective release of VCM into PBS lasted for 2 weeks from cements containing 1% VCM and for longer than 9 weeks from cements containing 5% VCM. The rate of release of VCM differed between cements with different crystallinities as well as between the two dissolution media, PBS and simulated body fluid. Mean concentration of VCM in the bone marrow tissue released from cements containing 5% VCM was 20 times the minimum inhibitory concentration 3 weeks after implantation in bone. Direct contact with new bone was observed with the cements containing 1% VCM. Slow delivery of VCM from a self-setting TTCP-DCPD apatite cement with low crystallinity could be used to treat MRSA osteomyelitis.

Rapid serum vancomycin assay by high-performance liquid chromatography using a semipermeable surface packing material column

A new isocratic high-performance liquid chromatographic (HPLC) assay has been developed for vancomycin that uses direct injection of microquantities of serum into a separation column filled with octyl-C(8) silica support that has a semipermeable surface. A mixture of disodium hydrogen phosphate buffer (pH 7.0) and acetonitrile is used as the mobile phase, and vancomycin is directly detected at 240 nm. The minimum limit of detection was 0.5 microg/ml at a signal-to-noise ratio of 3:1. Linearity was established from 0 to 100 microg/ml. The coefficient of variation for within-run reproducibility was 1.1-2.7% for a concentration range of 2.9-52.5 microg/ml; for day-to-day reproducibility it was 4.0% and 3.1% for a concentration range of 5.8-26.4 microg/ml, and the recovery rate was 94-105%. There was no interference from 41 antibiotics or other drugs currently in use. The correlation coefficient between the fluorescence polarization immunoassay (x) and this method (y) was 0.995 with a linear equation, y = 1.06x - 0.924. This method is simple, rapid, and provides an economical quantification of serum vancomycin.

Determination of vancomycin in human serum by micellar electrokinetic capillary chromatography with direct sample injection

BACKGROUND Vancomycin (VCM) has a bacteriostatic effect on gram-positive bacteria such as the methicillin-resistant Staphylococcus aureus. METHODS A new assay for measuring vancomycin concentration by micellar electrokinetic capillary chromatography using direct serum injection was developed. A borate buffer (pH 10.0) containing 100 mmol/l sodium dodecyl sulfate was used as an electrophoresis buffer, and the detection was at 210 nm. The migration time of vancomycin was approximately 7 min. RESULTS The linearity was from 0 to 100 microg/ml, with the limit of detection of 1.0 microg/ml (S/N=3). The within-run CV was 3.99-5.53%, and the recovery rate was 91-103% for a concentration range of 6.5-45.5 microg/ml. The between-day CV was 6.76% at 22.2 microg/ml. There was no interference from 32 other antibiotics. The correlation coefficient between the assay and fluorescence polarization immunoassay and direct injection HPLC was 0.982 and 0.985, respectively. The assay required no sample preparation of serum and used only microquantities of an electrophoresis buffer and samples. CONCLUSIONS This assay is cost-effective and suitable for routine clinical use.

Development and validation of a MEKC method for the direct determination of cefozopran in human serum

A method for determining the concentration of cefozopran, a cephem anti-microbial agent which has a broad spectrum, in human serum using micellar electrokinetic capillary chromatography (MEKC) by serum direct injection is developed and the validation of the assays of this method is performed. A borate buffer (25mM; pH 10.0) containing sodium dodecyl sulfate (SDS) (50mM) is used as a run buffer. The electrophoresis of serum samples is carried out at 25kV and the detection of cefozopran at 244nm as its absorption maximum at the cathodic side of the capillary. The migration time of cefozopran is 6.5min. Linearity (0-200mg/l) is good and limit of quantification is 0.5mg/l at a signal-to-noise ratio of 3. Coefficient of variation (CV) of intra-day precision and that of inter-day precision are 2.4-4.0% (7.3-92.0mg/l) and 2.9-7.7% (22.5-71.4mg/l), respectively, and the recovery rate is 92-109%. The detection results of 12 other cephem anti-microbial agents under the analytical conditions of this method show that the migration time of cefmetazole is identical with that of cefozopran, making it impossible to separate these two anti-microbial agents. This method is characterized by the fact that simple and economic determination can be achieved by directly injecting the serum samples of micro-quantities into the capillary.

Method development for determining the antibacterial linezolid in human serum by micellar electrokinetic capillary chromatography

A precise method for determining linezolid concentration in human serum by micellar electrokinetic capillary chromatography has been developed and validated. Serum was deproteinized with acetonitrile and etofylline was used as an internal standard. A borate buffer (pH 10.0; 25 mM) containing sodium dodecyl sulfate (80 mM) was used as a running buffer. Detection was performed at UV253 nm by applying 25 kV voltage to a fused-silica capillary tube. Migration time of linezolid was approximately 14 min. Good linearity (0-100 mg/l) was obtained and the limit of detection was 0.5 mg/l (S/N=3). This technique covered the clinical concentration (4 mg/l) measurement of this drug enough. The intra- and inter-day reproducibility was good. Serum recovery was 95-102%. No interference from other anti-microbial agents was observed. Linezolid after serum deproteinization showed high stability. This method was easy to operate as well as economical as a method for determining linezolid in serum.

Quantification of pilsicainide in serum by capillary electrophoresis.

A new method for determining pilsicainide concentration in serum by rapid and selective capillary electrophoresis has been developed and validated. For pretreatment, serum was made alkaline and then extracted with diethyl ether. Procainamide was used as an internal standard. Sodium dihydrogenphosphate buffer (pH 2.29; 0.1 M) was used as a running buffer. A fused-silica capillary tube was loaded with a voltage of 25 kV and detection was performed at UV 200 nm. Good linearity (0-2.5 microg/ml) was obtained with the minimum limit of detection being 0.04 microg/ml serum (signal-to-noise ratio, 3:1). The R.S.D. of within-run reproducibility was 0.798-2.32%, that of between-run reproducibility was 4.74-5.12% and the recovery rate was 61-63%. Disopyramide, another anti-arrhythmic drug, was close to pilsicainide in terms of migration time. This method was applied to determination of pilsicainide in serum samples.